The Açaí Berry COVID-19 Anti-Inflammation Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

480 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-04

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Açaí trial will be testing if the açaí berry extract, a safe natural product with anti-inflammatory properties, can be used as a treatment option in adult patients with COVID-19 in the community.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exploring the Role of Almonds in Enhancing Immune Strength

NCT05059639

Immune Health

COMPLETED NA

Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities

NCT01990391

Dyslipidemia Oxidative Stress

COMPLETED NA

Peanut Consumption on Cognitive, Weight, and Inflammation

NCT06127511

Cognitive Performance Inflammation Weight Change, Body +1 more

RECRUITING NA

Particle Sizing of Masticated Tree Nuts - Pistachios and Brazils

NCT02497768

Healthy

UNKNOWN NA

Effects of Almonds on Immune Health and Responsiveness

NCT05530499

Diet Intervention

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The current COVID-19 pandemic is caused by the novel coronavirus (SARS-Cov-2). The virus origins have been studied and evidence so far suggests it originates in bats, with spread to humans likely mediated by an intermediate mammalian. Bats have a dampened Nod-like receptor family, pyrin-containing 3 (NLRP3)-mediated inflammation. Dampening NLRP3-mediated inflammation has been associated with the asymptotic viral status, therefore it is plausible that the pathogenic inflammatory response of SARS-CoV-2 might be associated with activation of NLRP3 inflammasome. Data show that the natural extract of Açaí Palm Berry (Euterpe oleracea Mart.) is a potent inhibitor of NLRP3. This is a safe, inexpensive, and readily available natural health supplement which could be a rapid response treatment intervention for patients with COVID-19.

Our primary objective is to establish whether açai palm berry extract (Euterpe oleracea), given to community-dwelling adult patients diagnosed with COVID-19, compared to placebo, improves outcomes over 30 days on the 7-point ordinal scale described by Cao et al, and which is being used widely in COVID-19 trials with the aim of harmonizing endpoints. This study will be a prospective, double-blinded, placebo-controlled, randomized, multicentre clinical trial of Açaí Palm Berry extract in adult patients tested positive for SARS-Cov-2 in the last 7 days and that are currently being treated in the outpatient setting. The intervention group will receive 3 capsules of 520mg (one capsule every eight hours) of Acai Palm Berry extract (Nature's Way, NPN80038874) for 30 days. The non-intervention group will receive placebo pills, on top of standard clinical care. Our main endpoint will be the 7-point ordinal scale.

This project has the benefit of offering a safe and widely used natural extract as a potential treatment strategy to decrease inflammation and improve disease outcomes in patients with COVID-19. With no vaccine currently available, the search for effective treatments is a timely approach. The potential impact of such a therapeutic agent, if effective, can be quite vast given that it can be readily used by anyone and, most importantly, is affordable in many countries.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective, double-blinded, placebo-controlled, randomized, multicentre clinical trial

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double blinding, using placebo pills.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Açaí palm berry extract

Açaí palm berry extract is a powerful antioxidant with no known side-effects and is widely consumed in Brazil. Açaí palm berry chemical composition has been established and includes several antioxidants - gallic acid, catechin, chlorogenic acid, caffeic acid, p-coumaric acid, epicatechin, orientin, cyanidin-3-0-glucoside, luteolin and apigenin. Orientin is the most concentrated compound (7,96mg/g) and this compound is able to modulate the NLRP3 inflammasome.

Group Type EXPERIMENTAL

Açaí palm berry extract - natural product

Intervention Type DIETARY_SUPPLEMENT

Patients will be prescribed to take 1 capsule (520mg) of Açaí Palm Berry every 8 hours for a total of 3 capsules a day, during 30 days. Total dose: 1,560mg/day of Açaí Berry extract.

Placebo arm

This study will be double-blinded and placebo-controlled. To ensure double-blinding, placebo and active compound capsules will be over-encapsulated with DBCAPS® capsules, which were developed with a tamper-evident design to address the clinical trial challenges of testing without bias. These capsules are made of gelatin and have no interaction with bioavailability.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Patients will take 1 placebo pill every 8 hours (total of 3 capsules a day) for 30 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Açaí palm berry extract - natural product

Patients will be prescribed to take 1 capsule (520mg) of Açaí Palm Berry every 8 hours for a total of 3 capsules a day, during 30 days. Total dose: 1,560mg/day of Açaí Berry extract.

Intervention Type DIETARY_SUPPLEMENT

Placebo

Patients will take 1 placebo pill every 8 hours (total of 3 capsules a day) for 30 days.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults over 40 years of age; and
* Mild to moderate symptoms including fever, dry cough, and tiredness; and
* Tested positive for SARS-Cov-2, via virological diagnosis (PCR), in the last 7 days; and
* Not hospitalized at the time of randomization, with no limitations on activities; and
* Willingness to complete questionnaires and records associated with the study.

Exclusion Criteria

* Hospitalized patients at the time of enrollment; or
* Known allergy to study medication or its non-medicinal ingredients; or
* Currently taking açai extract or juice; or
* Chronic severe renal impairment (creatinine clearance \<30 mL/min or on renal replacement therapy); or
* Pregnant or breastfeeding patients; or
* Women who are planning to become pregnant during the study; or
* End-stage cancer or patients in whom imminent demise is anticipated and there is no commitment to active ongoing intervention; or
* Unable to provide informed consent; or
* Patients taking antiplatelet/blood-thinning medication; or
* Patients with unstable metabolic disease/chronic diseases/ diseases with any comorbidities and/or any serious medical condition or abnormality of clinical laboratory tests that precludes the patient's safe participation in and completion of the study or puts them in a greater risk of developing severe symptoms (e.g. Individuals with an acute infectious disease, immune-compromised, self-reported confirmation of HIV, other lung diseases such as asthma, emphysema, neurological conditions); or
* Patients who participated in other clinical research studies 30 days prior to screening; or
* Patients who are participating in another clinical trial at the same time.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No